01—Abstract
Summary
Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc.'s 2023 Form 10-K filing reveals a significant revenue decline, primarily driven by the substantial decrease in sales of its COVID-19 related products, Comirnaty and Paxlovid.
Despite this, the company completed the transformative acquisition of Seagen, significantly bolstering its oncology portfolio with the addition of four in-line medicines and a promising pipeline. Looking ahead, Pfizer is focusing on strategic priorities including achieving oncology leadership, advancing its pipeline for future growth, maximizing the performance of its newer products, and optimizing its cost structure. The company is navigating a dynamic market influenced by increasing pricing pressures, the ongoing patent expirations of key products, and evolving regulatory landscapes globally, including the impact of the Inflation Reduction Act (IRA) in the U.S. Pfizer's robust R&D efforts and strategic business development activities are key to its long-term value creation strategy.
02—Key points
Key Highlights
- Total revenues decreased by 42% to $58.5 billion in 2023, largely due to a significant drop in COVID-19 product sales (Comirnaty and Paxlovid).
- The acquisition of Seagen was completed in December 2023, adding transformative cancer medicines and strengthening Pfizer's oncology capabilities.
- Excluding COVID-19 products, total revenues increased by 7% operationally, driven by growth in products like Nurtec ODT/Vydura, Oxbryta, Abrysvo, Vyndaqel family, and Eliquis.
- Pfizer is implementing an enterprise-wide cost realignment program expected to deliver at least $4 billion in net cost savings by 2024, with approximately $1 billion in annual cost synergies expected from the Seagen acquisition by 2026.
- The company anticipates a moderate impact from patent expiries in 2024-2025 but expects a more significant impact from 2026 through 2030 as several key products face patent expirations.
- Pfizer continues to invest heavily in R&D, with a focus on its core therapeutic areas including inflammation and immunology, internal medicine, oncology, rare diseases, vaccines, and anti-infectives.
- The company maintained its commitment to shareholder returns, declaring a quarterly dividend of $0.42 per share, marking its 341st consecutive quarterly dividend.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 22, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $59.55B$101.17B | −41.1% |
| Cost of Revenue | $24.95B$34.34B | −27.3% |
| Gross Profit | $34.60B$66.83B | −48.2% |
| SG&A Expenses | $14.77B$13.68B | +8.0% |
| Interest Expense | $2.21B$1.24B | +78.4% |
| Net Income | $2.12B$31.37B | −93.2% |
| EPS (Basic) | $0.38$5.59 | −93.2% |
| EPS (Diluted) | $0.37$5.47 | −93.2% |
| Shares Outstanding (Basic) | 5.64B5.61B | +0.6% |
| Shares Outstanding (Diluted) | 5.71B5.73B | −0.4% |
05—Questions
Frequently Asked Questions
What is the primary reason for Pfizer's revenue decline in 2023?
Pfizer's total revenues decreased by 42% to $58.5 billion in 2023 compared to 2022. This significant decline was primarily driven by a substantial reduction in sales of its COVID-19 related products, Comirnaty (COVID-19 vaccine) and Paxlovid (COVID-19 treatment). Excluding these products, Pfizer's revenue grew by 7% operationally, indicating the underlying strength of its non-COVID-19 portfolio.
What impact does the Seagen acquisition have on Pfizer's business?
The acquisition of Seagen, completed in December 2023 for $44.2 billion, significantly strengthens Pfizer's oncology portfolio. Seagen brings four in-line cancer medicines (Padcev, Adcetris, Tukysa, and Tivdak) and a pipeline of innovative antibody-drug conjugate (ADC) therapies. This acquisition is a key part of Pfizer's strategy to achieve leadership in oncology and is expected to generate approximately $1 billion in annual cost synergies by 2026.
What are Pfizer's key strategic priorities for the future?
Pfizer's key priorities for 2024 include achieving world-class oncology leadership, delivering the next wave of pipeline innovation, maximizing the performance of its new products, expanding margins by realigning its cost base, and allocating capital to enhance shareholder value. The company is focused on advancing its R&D pipeline and pursuing strategic business development opportunities to drive long-term growth.
What is Pfizer's outlook regarding patent expirations?
Pfizer anticipates a moderate impact from patent expirations on its revenues in 2024 and 2025. However, the company expects a more significant impact from patent expiries between 2026 and 2030 as several of its key products approach patent expiry, leading to increased generic competition.
06—Continue